A detailed history of Farallon Capital Management LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Farallon Capital Management LLC holds 5,861,006 shares of PTGX stock, worth $230 Million. This represents 1.32% of its overall portfolio holdings.

Number of Shares
5,861,006
Previous 5,840,773 0.35%
Holding current value
$230 Million
Previous $202 Million 30.15%
% of portfolio
1.32%
Previous 0.98%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$33.72 - $47.33 $682,256 - $957,627
20,233 Added 0.35%
5,861,006 $263 Million
Q2 2024

Aug 14, 2024

BUY
$24.66 - $34.8 $2.51 Million - $3.54 Million
101,800 Added 1.77%
5,840,773 $202 Million
Q1 2024

May 15, 2024

BUY
$21.79 - $32.15 $98,991 - $146,057
4,543 Added 0.08%
5,738,973 $166 Million
Q4 2023

Feb 14, 2024

BUY
$14.05 - $23.44 $80.6 Million - $134 Million
5,734,430 New
5,734,430 $131 Million
Q3 2023

Nov 14, 2023

BUY
$16.68 - $23.66 $90.8 Million - $129 Million
5,446,430 New
5,446,430 $90.8 Million
Q2 2023

Aug 14, 2023

BUY
$18.02 - $29.36 $34.2 Million - $55.7 Million
1,896,416 Added 72.52%
4,511,430 $125 Million
Q1 2023

May 15, 2023

SELL
$10.78 - $25.38 $11.2 Million - $26.3 Million
-1,036,873 Reduced 28.39%
2,615,014 $60.1 Million
Q3 2022

Nov 14, 2022

SELL
$7.86 - $11.71 $382,947 - $570,522
-48,721 Reduced 1.32%
3,651,887 $30.8 Million
Q2 2022

Aug 15, 2022

BUY
$7.06 - $25.52 $18.1 Million - $65.5 Million
2,566,151 Added 226.2%
3,700,608 $29.3 Million
Q1 2022

May 16, 2022

SELL
$23.34 - $36.08 $18.3 Million - $28.2 Million
-782,677 Reduced 40.83%
1,134,457 $26.9 Million
Q4 2021

Feb 14, 2022

SELL
$17.63 - $37.1 $8.37 Million - $17.6 Million
-474,866 Reduced 19.85%
1,917,134 $65.6 Million
Q3 2021

Nov 15, 2021

BUY
$12.95 - $49.69 $807,044 - $3.1 Million
62,320 Added 2.68%
2,392,000 $42.4 Million
Q2 2021

Aug 13, 2021

SELL
$25.57 - $44.88 $2.44 Million - $4.28 Million
-95,320 Reduced 3.93%
2,329,680 $105 Million
Q4 2020

Feb 16, 2021

SELL
$18.49 - $25.13 $6.01 Million - $8.17 Million
-325,000 Reduced 11.82%
2,425,000 $48.9 Million
Q3 2020

Nov 16, 2020

BUY
$15.19 - $22.4 $3.8 Million - $5.6 Million
250,000 Added 10.0%
2,750,000 $53.8 Million
Q2 2020

Aug 14, 2020

BUY
$6.19 - $18.84 $6.19 Million - $18.8 Million
1,000,000 Added 66.67%
2,500,000 $44.2 Million
Q2 2019

Aug 14, 2019

SELL
$8.98 - $12.96 $2.6 Million - $3.76 Million
-290,000 Reduced 16.2%
1,500,000 $18.2 Million
Q1 2019

May 15, 2019

SELL
$6.5 - $13.77 $2.66 Million - $5.64 Million
-409,674 Reduced 18.62%
1,790,000 $22.5 Million
Q4 2018

Feb 14, 2019

SELL
$6.3 - $10.44 $274,226 - $454,432
-43,528 Reduced 1.94%
2,199,674 $14.8 Million
Q3 2018

Nov 14, 2018

BUY
$6.82 - $11.26 $9.09 Million - $15 Million
1,332,973 Added 146.44%
2,243,202 $23.1 Million
Q2 2018

Aug 14, 2018

SELL
$5.99 - $9.1 $618,593 - $939,766
-103,271 Reduced 10.19%
910,229 $6.12 Million
Q1 2018

May 15, 2018

BUY
$8.46 - $23.08 $960,210 - $2.62 Million
113,500 Added 12.61%
1,013,500 $8.71 Million
Q4 2017

Feb 14, 2018

BUY
$14.47 - $20.8 $13 Million - $18.7 Million
900,000
900,000 $18.7 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.93B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Farallon Capital Management LLC Portfolio

Follow Farallon Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farallon Capital Management LLC with notifications on news.